A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

Summary

This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) or participants who would have been eligible for the lead-in study but were not enrolled (de novo). The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TB006. The total study duration for each participant will be up to 113 weeks.

Timeline

Start

2022-09-15

Primary completion

2023-11-17

Completion

2023-11-17

Outcome

Outcome not reported

Stopped: “Resource Constraints”

Drugs

Indications